• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺癌治疗的新见解与旧认识

Old and new insights in the treatment of thyroid carcinoma.

作者信息

Gasent Blesa Joan Manel, Grande Pulido Enrique, Provencio Pulla Mariano, Alberola Candel Vicente, Laforga Canales Juan Bautista, Grimalt Arrom Miguel, Martin Rico Patricia

机构信息

Departament d'Oncologia Mèdica, Hospital de Dénia, Marina Salud, Partida de Beniadlà s/n, Dénia, Alacant, Spain.

出版信息

J Thyroid Res. 2010 Apr 13;2010:279468. doi: 10.4061/2010/279468.

DOI:10.4061/2010/279468
PMID:21048836
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2956973/
Abstract

Thyroid cancer is the endocrine tumor that bears the highest incidence with 33 550 new cases per year. It bears an excellent prognosis with a mortality of 1530 patients per year (Jemal et al.; 2007). We have been treating patients with thyroid carcinoma during many years without many innovations. Recently, we have assisted to the development of new agents for the treatment of this disease with unexpected good results. Here we present a review with the old and new methods for the treatment of this disease.

摘要

甲状腺癌是发病率最高的内分泌肿瘤,每年有33550例新发病例。其预后良好,每年死亡率为1530例患者(杰马尔等人;2007年)。多年来我们一直在治疗甲状腺癌患者,没有太多创新。最近,我们参与了治疗这种疾病的新药物的研发,取得了意想不到的良好效果。在此,我们对这种疾病的新旧治疗方法进行综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/159c/2956973/626344137498/JTR2010-279468.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/159c/2956973/626344137498/JTR2010-279468.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/159c/2956973/626344137498/JTR2010-279468.001.jpg

相似文献

1
Old and new insights in the treatment of thyroid carcinoma.甲状腺癌治疗的新见解与旧认识
J Thyroid Res. 2010 Apr 13;2010:279468. doi: 10.4061/2010/279468.
2
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
3
Robotic total thyroidectomy with modified radical neck dissection via unilateral retroauricular approach.经单侧耳后入路机器人辅助全甲状腺切除术并改良根治性颈清扫术
Ann Surg Oncol. 2014 Nov;21(12):3872-5. doi: 10.1245/s10434-014-3896-y. Epub 2014 Sep 17.
4
Thyroid Cancer: 20-Year Comparative Mortality and Survival Analysis of Six Thyroid Cancer Histologic Subtypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration (SEER*Stat 8.3.2) A Systematic Review of 145,457 Cases for Diagnosis Years 1993-2013.甲状腺癌:按年龄、性别、种族、分期、队列进入时间周期和疾病持续时间对六种甲状腺癌组织学亚型进行的20年死亡率和生存率比较分析(SEER*Stat 8.3.2) 对1993 - 2013年诊断的145,457例病例的系统评价
J Insur Med. 2018 Jan;47(3):143-158. doi: 10.17849/insm-47-03-143-158.1.
5
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.1974 - 2013年美国甲状腺癌发病率和死亡率趋势
JAMA. 2017 Apr 4;317(13):1338-1348. doi: 10.1001/jama.2017.2719.
6
Robot-assisted Sistrunk's operation, total thyroidectomy, and neck dissection via a transaxillary and retroauricular (TARA) approach in papillary carcinoma arising in thyroglossal duct cyst and thyroid gland.经腋后(TARA)入路机器人辅助施行 Sistrunk 手术、甲状腺全切除术和颈淋巴结清扫术治疗甲状舌管囊肿和甲状腺起源的乳头状癌
Ann Surg Oncol. 2012 Dec;19(13):4259-61. doi: 10.1245/s10434-012-2674-y. Epub 2012 Oct 16.
7
[Endocrine surgery. The ninth report: the latest data on and clinical characteristics of the epidemiology of thyroid carcinoma].
J Nippon Med Sch. 2003 Feb;70(1):57-61. doi: 10.1272/jnms.70.57.
8
[Papillary thyroid cancer: case reports of four family cases].
Rev Chil Pediatr. 2014 Jun;85(3):351-8. doi: 10.4067/S0370-41062014000300012.
9
Thyroid cancer: trends in incidence, mortality and clinical-pathological patterns in Zhejiang Province, Southeast China.甲状腺癌:中国东南部浙江省的发病、死亡趋势和临床病理特征。
BMC Cancer. 2018 Mar 15;18(1):291. doi: 10.1186/s12885-018-4081-7.
10
Pediatric thyroid cancer: An update from the SEER database 2007-2012.儿童甲状腺癌:来自监测、流行病学和最终结果(SEER)数据库2007 - 2012年的最新情况
Int J Pediatr Otorhinolaryngol. 2016 Oct;89:121-6. doi: 10.1016/j.ijporl.2016.08.005. Epub 2016 Aug 8.

引用本文的文献

1
An Occupational Study in Nurses: Prevalence of Thyroid Nodules and Cancer in Comparison to Health Check-up Female.一项针对护士的职业研究:甲状腺结节和癌症的患病率与健康体检女性的比较。
Clin Exp Otorhinolaryngol. 2016 Sep;9(3):252-6. doi: 10.21053/ceo.2015.01109. Epub 2016 Jun 18.
2
Factors related to mortality in patients with papillary and follicular thyroid cancer in long-term follow-up.长期随访中甲状腺乳头癌和滤泡状甲状腺癌患者的死亡率相关因素。
J Endocrinol Invest. 2014 Dec;37(12):1195-200. doi: 10.1007/s40618-014-0131-4. Epub 2014 Jul 19.
3
Proteomic profiling of thyroid papillary carcinoma.

本文引用的文献

1
Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.甲状腺癌术后低活性(2.0 GBq;54 mCi)放射性碘残余甲状腺组织消融:低风险患者中激素撤停与重组人促甲状腺素使用的比较。
Eur J Endocrinol. 2009 Mar;160(3):431-6. doi: 10.1530/EJE-08-0669. Epub 2008 Dec 12.
2
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.阿昔替尼对晚期甲状腺癌的所有组织学亚型均为有效的治疗方法:一项II期研究的结果
J Clin Oncol. 2008 Oct 10;26(29):4708-13. doi: 10.1200/JCO.2007.15.9566. Epub 2008 Jun 9.
3
甲状腺乳头状癌的蛋白质组学分析
J Thyroid Res. 2012;2012:815079. doi: 10.1155/2012/815079. Epub 2012 Feb 12.
4
Clinical utility of serum interleukin-8 and interferon-alpha in thyroid diseases.血清白细胞介素-8和干扰素-α在甲状腺疾病中的临床应用价值
J Thyroid Res. 2011 Mar 8;2011:270149. doi: 10.4061/2011/270149.
Phase II trial of sorafenib in advanced thyroid cancer.
索拉非尼用于晚期甲状腺癌的II期试验。
J Clin Oncol. 2008 Oct 10;26(29):4714-9. doi: 10.1200/JCO.2008.16.3279. Epub 2008 Jun 9.
4
Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.重组人促甲状腺素辅助放射性碘残留消融术的短期临床复发率与传统甲状腺激素撤药法相似。
J Nucl Med. 2008 May;49(5):764-70. doi: 10.2967/jnumed.107.049072. Epub 2008 Apr 15.
5
A phase II study of gefitinib in patients with advanced thyroid cancer.吉非替尼用于晚期甲状腺癌患者的II期研究。
Thyroid. 2008 Mar;18(3):317-23. doi: 10.1089/thy.2007.0120.
6
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.500例连续乳头状甲状腺癌患者中BRAF V600E突变与不良临床病理结局的相关性
J Clin Endocrinol Metab. 2007 Nov;92(11):4085-90. doi: 10.1210/jc.2007-1179. Epub 2007 Sep 4.
7
Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years.间变性甲状腺癌:过去5年转诊至单一机构的30例连续患者的临床结局。
Eur J Endocrinol. 2007 Apr;156(4):425-30. doi: 10.1530/EJE-06-0677.
8
Anaplastic thyroid carcinoma: an overview.间变性甲状腺癌:概述
Curr Oncol Rep. 2007 Mar;9(2):152-8. doi: 10.1007/s11912-007-0014-3.
9
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.凡德他尼(ZD6474):一种口服有效的受体酪氨酸激酶抑制剂,可选择性靶向对肿瘤生长和血管生成至关重要的信号通路。
Expert Opin Investig Drugs. 2007 Feb;16(2):239-49. doi: 10.1517/13543784.16.2.239.
10
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.一项针对晚期实体瘤患者的间歇性高剂量吉非替尼与固定剂量多西他赛的I期试验。
Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75. doi: 10.1007/s00280-006-0286-6. Epub 2006 Aug 1.